Results 11 to 20 of about 212,106 (307)

Epigenetic insights into minimal residual disease detection in cancer [PDF]

Genes and Diseases
Lingao Ju, Gang Wang, Zilin Xu, Wan Xiang, Hongwei Peng, Mengxue Yu, Shenjuan Li, Yi Zhang, Kaiyu Qian, Yu Xiao   +9 more
doaj   +3 more sources

Minimal Residual Disease, Metastasis and Immunity [PDF]

Biomolecules, 2021
Progression from localized to metastatic disease requires cancer cells spreading to distant organs through the bloodstream. Only a small proportion of these circulating tumor cells (CTCs) survives dissemination due to anoikis, shear forces and ...
Jordi Badia-Ramentol, Jenniffer Linares, Andrea Gómez-Llonin, Alexandre Calon   +3 more
doaj   +3 more sources

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications

Frontiers in Oncology, 2022
Multiple Myeloma (MM), the second most common hematologic malignancy, has been the target of many therapeutic advances over the past two decades. The introduction of novel agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal ...
Charalampos Charalampous, Taxiarchis Kourelis   +1 more
doaj   +1 more source

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Journal of Hematology & Oncology, 2021
The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions in MM
Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado, Santiago Barrio, Thomas Martin, Maria Teresa Cedena, Jeffrey Wolf   +19 more
doaj   +1 more source

Minimal residual disease [PDF]

Current Opinion in Hematology, 1999
Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire   +3 more sources

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

BMC Cancer, 2022
Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy.
Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær   +26 more
doaj   +1 more source

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios

Frontiers in Oncology, 2022
Circulating-tumor DNA (ctDNA) has emerged as an important biomarker for monitoring disease status in cancer patients. Different ctDNA testing platforms have shown promising results in the early detection of disease, monitoring response to treatment, and ...
Karam Khaddour, Karam Khaddour, Alice Zhou, Omar H. Butt, Griffin Budde, Allyson Koyen Malashevich, George Ansstas   +6 more
doaj   +1 more source

Minimal residual disease in multiple myeloma: current status

Biomarker Research, 2021
Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM.
Hong Ding, Juan Xu, Zhimei Lin, Jingcao Huang, Fangfang Wang, Yan Yang, Yushan Cui, Hongmei Luo, Yuhan Gao, Xinyu Zhai, Weicui Pang, Li Zhang, Yuhuan Zheng   +12 more
doaj   +1 more source

Re: Molecular testing to deliver personalised chemotherapy recommendations

BMC Medicine, 2023
Background There is an increasing focus over time on the discovery and validation of biomarkers in cancer medicine, which can inform the identification of patients that are most likely to benefit from treatment, which therapy is most likely to be ...
Peter Gibbs, Wei Hong, Jeanne Tie
doaj   +1 more source

Minimal residual disease in EGFR-mutant non-small-cell lung cancer

Frontiers in Oncology, 2022
Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for EGFR-mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual ...
Nathan T. Bain, Yang Wang, Surein Arulananda, Surein Arulananda, Surein Arulananda, Surein Arulananda   +5 more
doaj   +1 more source